Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Supreme Court Declines To Hear Cardizem CD, Hytrin Antitrust Cases

This article was originally published in The Pink Sheet Daily

Executive Summary

The two cases created an apparent disagreement among the federal appellate circuits on the legality of “reverse payments” from a brand company to delay a generic’s entry.

You may also be interested in...



Abbott/Sandoz’ Hytrin Agreement Violates Antitrust Law, Judge Says

A provision under which Sandoz (formerly Geneva) agreed not to market generic terazosin until an appellate ruling in underlying patent litigation “exceeded the scope” of the potential exclusionary effect of Abbott’s patent, court says. The ruling marks the second time the judge has found the agreement to violate antitrust law.

Abbott/Sandoz’ Hytrin Agreement Violates Antitrust Law, Judge Says

A provision under which Sandoz (formerly Geneva) agreed not to market generic terazosin until an appellate ruling in underlying patent litigation “exceeded the scope” of the potential exclusionary effect of Abbott’s patent, court says. The ruling marks the second time the judge has found the agreement to violate antitrust law.

Cardizem CD Antitrust Ruling Should Stand, FTC Tells Supreme Court

Key aspects of the agreement between Andrx and Hoechst Marion Roussel, such as "reverse payments" and interim settlement, are unlikely to arise in future deals between brand and generic companies, the Federal Trade Commission and Solicitor General tell the high court.

Topics

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel